Akums

Delhi, India Founded: 2004 • Age: 22 yrs Listed
CDMO focusing on spectrum of dosage forms and therapeutic segments
Request Access
Report Incorrect Data
Page last updated

About Akums

Akums is a publicly listed company based in Delhi (India) founded in 2004. CDMO focusing on spectrum of dosage forms and therapeutic segments. Akums has raised $70 million across 1 funding round from investors including Quadria Capital. The company has 17,860 employees. Akums has completed 2 acquisitions, including Ankur Drugs and Parabolic Drugs. Akums was last valued at $459.31 million in November 2019. Its website akums.in draws about 25 thousand monthly visits. Its Indian entity Akums Drugs And Pharmaceuticals Limited reported revenue of ₹4,488 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Jubilant Life Sciences, Nectar Lifesciences and Windlas; 2 of its 3 listed competitors have raised funding.

Company details

Akums was founded in 2004 and is headquartered in Delhi, India. As a contract development and manufacturing organization in the pharmaceutical sector, formulations are produced and exported across multiple dosage forms, including oral solids, liquids, sterile injectables, hormonals, ointments, cosmetics, Ayurvedics, and nutraceuticals. Therapeutic areas addressed encompass respiratory, neurology, analgesics, cardiovascular, immunomodulators, and supportive care.

Recognitions & Rankings of Akums

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#491
Valuation
₹9,840 Cr
  • Headquarters Delhi, India
  • Employees 17,860
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website akums.in
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Akums Drugs And Pharmaceuticals Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹10,706 Cr

    AKUMS · NSE

  • Share Price
    ₹669.00

    -1.65% today

  • Revenue
    ₹4,359 Cr

    FY 2025-26 · +5.9% YoY

  • EBITDA
    ₹502 Cr

    Margin 11.5%

  • Net Profit
    ₹269 Cr

    FY 2025-26 · -16.7% YoY

  • P/E (TTM)
    35.8x

    P/B 3.3x

  • ROE
    8.1%

    ROCE 12.5%

  • Debt / Equity
    0.04

    Interest cover 27.1x

  • Total Equity Funding
    $70M (USD)

    in 1 rounds

  • Latest Funding Round
    $70M (USD), Private Equity Round

    Nov 2019

  • Investors
    Quadria Capital
  • Employee Count
    17,860
  • Investments & Acquisitions
    Ankur Drugs

    & 1 more

Apps and channels of Akums

its YouTube channel Akums Drugs and Pharmaceuticals Ltd. has 1.34K subscribers and 30 videos.

Akums Drugs and Pharmaceuticals Ltd.
YouTube 1.34K subscribers 30 videos Science & Technology
Open channel

Videos from Akums

The most watched videos on Akums's YouTube channel, Akums Drugs and Pharmaceuticals Ltd. (1.34K subscribers). Click a video to play it here.

Akums X Caregen | Dr. CYJ Hair Fillers
135 views
Akums - Annual General Meeting
112 views
Akums: Empowering Pharma Growth & Market Expansion
91 views
Akums | Growth is always beside you
77 views

More on Akums Drugs and Pharmaceuticals Ltd..

Funding Insights of Akums

Akums has successfully raised a total of $70M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $70 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $70M
  • Total Rounds 1
  • Last Round Private Equity Round — $70M
  • First Round $70M

    (Nov 2019)

  • Investors Count 1

All 1 funding rounds of Akums with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2019$70MPrivate Equity Round$459.31MQuadria Capital
–
Valuation history
DateValuationStage
Nov 2019$459.31M••••••••

Last known valuation $459.31M (Nov 2019). 1 investors in total: 1 institutional.

Investors in Akums

Akums has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Quadria Capital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Quadria Capital
Healthcare private equity investments focused on Asian markets.
2012quadriacapital.comSingapore, Singapore
Premium access

Investor details for Akums

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Akums Drugs And Pharmaceuticals Limited (Akums)

Akums Drugs And Pharmaceuticals Limited is the primary company behind Akums. The boards of the 6 registered companies of Akums currently have 25 directors; the longest-serving is Sandeep Jain, appointed in 2004. 99 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sandeep Jain
DIN 00323476
Managing Director19 Apr 200422 yrs 6 moAkums Drugs And Pharmaceuticals Limited
Sanjeev Jain
DIN 00323433
Managing Director19 Apr 200422 yrs 6 moAkums Drugs And Pharmaceuticals Limited
Khyali Dutt Sharma
DIN 02942552
Whole-time director01 Feb 201016 yrs 8 moMaxcure Nutravedics Limited
Suman
DIN 02326675
Director22 Jul 201511 yrs 3 moMalik Lifesciences Private Limited
Yogesh Chandra Bhatt
DIN 06787063
Director30 Oct 20178 yrs 11 moAvha Lifesciences Private Limited
Pooja Das
DIN 06762847
Director30 Oct 20178 yrs 11 moAvha Lifesciences Private Limited
Parveen Soni
DIN 00332902
Director10 Dec 20196 yrs 10 moMaxcure Nutravedics Limited
Nidhi Sharma
DIN 03170443
Director10 Dec 20196 yrs 10 moMaxcure Nutravedics Limited
Manan Jain
DIN 08632719
Director16 Dec 20196 yrs 10 moAvha Lifesciences Private Limited
Rama Shanker
DIN 06932049
CFO02 Mar 20206 yrs 7 moAkums Lifesciences Limited
Vijaypal Singh Rawat
DIN 06744017
Whole-time director13 Aug 20206 yrs 2 moMalik Lifesciences Private Limited
Dharamvir Malik
DIN 06758188
Director31 Mar 20215 yrs 6 moAkums Lifesciences Limited
Samandar Singh Dhakad
DIN 06726622
Director26 Aug 20215 yrs 1 moAkums Healthcare Limited, Malik Lifesciences Private Limited
Kewal Kundanlal Handa
DIN 00056826
Director16 Mar 20224 yrs 7 moAkums Drugs And Pharmaceuticals Limited
Matangi Gowrishankar
DIN 01518137
Director16 Mar 20224 yrs 7 moAkums Drugs And Pharmaceuticals Limited
Geetanjali Sharma
DIN 10413416
Company Secretary17 Sep 20224 yrs 1 moMaxcure Nutravedics Limited
Himanshu Umeshbabu Saxena
DIN 08247669
Whole-time director13 Feb 20233 yrs 8 moAkums Lifesciences Limited
Manmohan Singh
DIN 02994045
Director23 Aug 20233 yrs 2 moMalik Lifesciences Private Limited
Basant Kumar Singh
DIN 09523959
Director04 Dec 20232 yrs 10 moAkums Healthcare Limited
Satwinder Singh
DIN 00164903
Director17 Jan 20242 yrs 9 moAkums Drugs And Pharmaceuticals Limited
Sunil Kumar Thakur
DIN 03266370
Nominee Director17 Jan 20242 yrs 9 moAkums Drugs And Pharmaceuticals Limited
Sanjay Sinha
DIN 03627342
Whole-time director17 Jan 20242 yrs 9 moAkums Drugs And Pharmaceuticals Limited
Anilkumar Arvindlal Amin
DIN 10594012
Director04 Jun 20251 yr 4 moAkums Drugs And Pharmaceuticals Limited
Dilip Kumar Gupta
DIN 07626666
Additional Director01 Jan 20269 moAkums Healthcare Limited
Lajpat Singh Rawat
DIN 02583673
Additional Director10 Feb 20268 moAkums Healthcare Limited

People of Akums

14 people are tracked at Akums (4 in leadership, 10 in team); the tracked headcount is 17,860.

NameRoleGroup
Sanjeev Jain
DirectorLeadership
Sandeep Jain
DirectorLeadership
Abhishek Saxena
EA To Group CEO (corporate Strategy)Leadership
Sanjay Pandeyy
Head-engineering And ProjectsLeadership
Dipti Saddar
HR ManagerTeam
Ashu Chaudhary
Human Resources SpecialistTeam
Divya S.
Manufacturing Human Resources ManagerTeam
Deepak Kumar
Human Resources ExecutiveTeam
Ravi Bijnor
Human Resources ExecutiveTeam
Abhishek Sharma
Senior Human Resources Manager (sales)Team
Rajesh Belwal
Deputy ManagerTeam
Pratibha Singh
Assistant Executive QualityTeam
Prerna Sharma
Senior Corporate HRTeam
Shruti Kaushik
HR (talent Acquisition)Team
Premium access

Complete people profiles for Akums

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Akums

Akums is a publicly listed company on the NSE with ticker symbol AKUMS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date06 Aug 2024
  • Listed onBSE: 544222 · NSE: AKUMS
  • Listed entityAkums Drugs and Pharmaceuticals Limited
  • Exchange sectorHealth technology
  • ISININE09XN01023
  • Share price₹769.95 (+0.08% on the day) · 2026-10-14
  • Market capitalisation₹12,091 Cr
  • Price to earnings40.4
  • EPS (diluted, trailing year)₹19.05
  • Dividend yield0.13%
  • Volume (last session)134,253

Financials of Akums

Exchange-reported figures of Akums Drugs And Pharmaceuticals Limited, the listed company behind Akums (NSE: AKUMS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,359 Cr
+5.8% YoY
EBITDA
₹502 Cr
+8.1% YoY
Profit After Tax
₹269 Cr
-16.7% YoY
Net Worth
₹3,313 Cr
+8.7% YoY
Total Assets
₹4,415 Cr
+37.0% YoY
Total Debt
₹157 Cr
+78.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,3594,1184,1783,6553,6722,7232,414
Revenue growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
EBITDA50246496.95219(105)227173
EBITDA margin+11.5%+11.3%+2.3%+6.0%-2.9%+8.4%+7.2%
Profit before tax382345(45.27)150(193)172114
Net profit269323(20.67)127(244)13044.09
Net profit margin+6.2%+7.8%-0.5%+3.5%-6.6%+4.8%+1.8%
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
Balance sheet
Total assets4,4153,2222,7132,4042,1091,6471,439
Net worth3,3133,047710717622885722
Total debt15788.22565619395130175
Cash & bank1,68157627715010367.87147
Net working capital2,5461,4021,1491,042943659679
Cash flow
Cash from operations1,18146549817731.8513128.13
Cash from investing(930)(548)(331)(305)(235)(109)(190)
Cash from financing33.8872.79(108)125236(91.46)233
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1671,1581,1601,0181,0241,0561,0101,033
Revenue growth (YoY)+13.9%+9.7%+14.8%-1.5%+0.5%---
Other income30.3835.3034.3332.3726.7325.7619.3417.17
EBITDA17515012994.4812993.92121121
EBITDA margin+15.0%+12.9%+11.1%+9.3%+12.6%+8.9%+12.0%+11.7%
Depreciation41.0740.1239.6537.8636.9240.0044.5234.87
Interest24.7623.8923.7423.3023.144.545.1311.90
Profit before tax13912199.5765.6995.6475.1491.0591.59
Tax38.2639.8731.8922.9830.96(74.47)24.7524.94
Net profit10181.3567.6842.7164.6815066.3066.65
EPS (₹)6.535.534.332.664.159.644.264.37
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3491,3121,4441,2871,162837737
Revenue growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
EBITDA90.96138(146)97.34(362)(223)39.93
EBITDA margin+6.7%+10.6%-10.1%+7.6%-31.2%-26.6%+5.4%
Profit before tax148208(103)150(335)(195)75.85
Net profit117158(157)231(383)11050.84
Net profit margin+8.6%+12.1%-10.9%+17.9%-32.9%+13.2%+6.9%
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
Balance sheet
Total assets2,5162,3741,7961,5211,3891,1761,262
Net worth2,4282,305144312186567712
Total debt59.2146.2926714614041.1335.80
Cash & bank77135673.318.8525.741.0072.48
Net working capital1,035530244148143230352
Cash flow
Cash from operations(2.15)91.0024894.0122855.57(21.75)
Cash from investing(24.97)(459)(165)(202)(298)(99.96)(242)
Cash from financing(3.00)375(20.74)89.9094.992.60302
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue392338369309332329337328
Revenue growth (YoY)+18.0%+2.9%+9.3%-5.8%+4.8%---
Other income26.1027.7329.6027.0828.5632.0533.8432.12
Total expenses344329348292288311303285
EBITDA48.519.0720.8716.9044.1017.7234.0343.07
EBITDA margin+12.4%+2.7%+5.7%+5.5%+13.3%+5.4%+10.1%+13.1%
Depreciation12.8012.4212.1510.6910.2510.0910.689.39
Interest2.482.592.462.082.912.632.294.18
Profit before tax59.3321.7935.8631.2159.5037.0554.9061.62
Tax14.506.607.757.7414.649.4713.7311.25

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1671,1581,1601,0181,0241,0561,0101,033
Revenue growth (YoY)+13.9%+9.7%+14.8%-1.5%+0.5%---
Other income30.3835.3034.3332.3726.7325.7619.3417.17
EBITDA17515012994.4812993.92121121
EBITDA margin+15.0%+12.9%+11.1%+9.3%+12.6%+8.9%+12.0%+11.7%
Depreciation41.0740.1239.6537.8636.9240.0044.5234.87
Interest24.7623.8923.7423.3023.144.545.1311.90
Profit before tax13912199.5765.6995.6475.1491.0591.59
Tax38.2639.8731.8922.9830.96(74.47)24.7524.94
Net profit10181.3567.6842.7164.6815066.3066.65
EPS (₹)6.535.534.332.664.159.644.264.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,3594,1184,1783,6553,6722,7232,414
Revenue growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
Other income12968.8234.0390.0722.8321.5027.49
Total expenses3,8573,6544,0813,4363,7772,4952,241
Employee cost754716647590508425439
EBITDA50246496.95219(105)227173
EBITDA margin+11.5%+11.3%+2.3%+6.0%-2.9%+8.4%+7.2%
Depreciation15515312611394.6869.8466.68
Interest94.0734.6050.6146.2516.666.7419.93
Profit before tax382345(45.27)150(193)172114
Tax1261.48(46.07)52.4857.6848.8370.17
Net profit269323(20.67)127(244)13044.09
Net profit margin+6.2%+7.8%-0.5%+3.5%-6.6%+4.8%+1.8%
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital30.6230.6228.6128.6114.311.301.30
Reserves & surplus3,2833,016681689608884721
Shareholders' funds (net worth)3,3133,047710717622885722
Minority interest17.7716.6010.996.193.202.29(1.51)
Secured loans72.9513.6639153735895.90140
Unsecured loans84.4874.5617482.1237.0334.0735.02
Total debt15788.22565619395130175
Total liabilities4,4153,2222,7132,4042,1091,6471,439
Assets
Gross block2,4102,2421,8821,6831,5181,321993
Net block1,4561,3971,1911,0971,021904645
Capital work in progress17716319510331.0717.0156.60
Investments0.140.140.140.140.3919.545.84
Inventories756681630730722430398
Sundry debtors797770834845884531582
Cash & bank balances1,68157627715010367.87147
Loans & advances327247200154154109117
Total current assets3,5602,2751,9411,8791,8641,1381,244
Total current liabilities1,014873792837921479565
Net working capital2,5461,4021,1491,042943659679
Total assets4,4153,2222,7132,4042,1091,6471,439
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10111151.6155.1422.0791.7920.51
Net cash from operating activities1,18146549817731.8513128.13
Net cash from investing activities(930)(548)(331)(305)(235)(109)(190)
Net cash from financing activities33.8872.79(108)125236(91.46)233
Net change in cash285(9.86)59.44(3.53)33.07(69.72)71.28
Closing cash1,68157627715010367.87147
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
EBITDA growth+8.1%+379.1%-55.8%+309.4%-146.1%+31.4%-
PBT growth+10.7%+9998.0%-+9998.0%-+51.3%+7.7%
Net income growth-16.7%+1660.6%-116.2%+152.3%-287.8%+194.2%-
Revenue CAGR (3Y)+6.1%+3.9%+15.4%+14.8%+30.5%+23.0%-
EBITDA CAGR (3Y)+31.8%--24.7%+8.2%-+22.4%-
Profitability & leverage
Net income margin+5.9%+8.4%+0.0%+2.7%-6.8%+4.5%+1.8%
Return on capital employed+12.5%+12.9%+1.2%+11.7%-9.4%+11.6%+9.3%
Return on net worth+8.1%+18.3%-2.2%+19.5%-33.3%+15.4%+6.0%
Debt / equity0.040.170.830.760.330.190.24
Long-term debt / equity0.020.060.240.180.030.020.01
Interest cover27.0711.12-176.4043.44-8.364.2818.75
Efficiency & per share
Fixed asset turnover1.872.002.342.282.662.352.43
Inventory turnover6.076.286.145.036.376.576.06
Debtors turnover5.565.134.984.235.194.894.15
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
Dividend per share (₹)3.000.000.000.000.000.000.00
Book value per share (₹)216.41199.0149.5950.1386.956,801.285,554.41
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue392338369309332329337328
Revenue growth (YoY)+18.0%+2.9%+9.3%-5.8%+4.8%---
Other income26.1027.7329.6027.0828.5632.0533.8432.12
Total expenses344329348292288311303285
EBITDA48.519.0720.8716.9044.1017.7234.0343.07
EBITDA margin+12.4%+2.7%+5.7%+5.5%+13.3%+5.4%+10.1%+13.1%
Depreciation12.8012.4212.1510.6910.2510.0910.689.39
Interest2.482.592.462.082.912.632.294.18
Profit before tax59.3321.7935.8631.2159.5037.0554.9061.62
Tax14.506.607.757.7414.649.4713.7311.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3491,3121,4441,2871,162837737
Revenue growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
Other income11312494.1296.1558.4854.5165.52
Total expenses1,2581,1731,5901,1891,5241,060697
Employee cost218202175147136123124
EBITDA90.96138(146)97.34(362)(223)39.93
EBITDA margin+6.7%+10.6%-10.1%+7.6%-31.2%-26.6%+5.4%
Depreciation45.5039.5532.6930.0027.7626.1025.26
Interest10.0415.3118.3113.183.650.824.34
Profit before tax148208(103)150(335)(195)75.85
Tax36.7246.8362.5224.8946.80(49.77)24.99
Net profit117158(157)231(383)11050.84
Net profit margin+8.6%+12.1%-10.9%+17.9%-32.9%+13.2%+6.9%
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital30.6230.6228.6128.6114.311.301.30
Reserves & surplus2,3972,275115283171566711
Shareholders' funds (net worth)2,4282,305144312186567712
Secured loans13.553.9322614612222.7135.80
Unsecured loans45.6642.3640.780.0018.0718.420.00
Total debt59.2146.2926714614041.1335.80
Total liabilities2,5162,3741,7961,5211,3891,1761,262
Assets
Gross block792683613532497463436
Net block425356317272253244242
Capital work in progress52.2356.748.6516.250.521.261.13
Investments36636613913914114965.35
Inventories23020216219717995.91123
Sundry debtors218206234256304212178
Cash & bank balances77135673.318.8525.741.0072.48
Loans & advances10569.2464.4358.9946.1943.02121
Total current assets1,324833533521555352494
Total current liabilities289303289373412122142
Net working capital1,035530244148143230352
Total assets2,5162,3741,7961,5211,3891,1761,262
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash76.4968.967.2325.490.1541.933.87
Net cash from operating activities(2.15)91.0024894.0122855.57(21.75)
Net cash from investing activities(24.97)(459)(165)(202)(298)(99.96)(242)
Net cash from financing activities(3.00)375(20.74)89.9094.992.60302
Net change in cash(30.11)7.5461.72(18.26)25.34(41.79)38.07
Closing cash77135673.318.8525.741.0072.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
EBITDA growth-34.3%+194.8%-250.0%+126.9%-62.5%-658.0%-
PBT growth-28.6%+9998.0%-+9998.0%-71.6%--32.3%
Net income growth-26.4%+200.6%-168.3%+160.2%-447.0%+117.0%-
Revenue CAGR (3Y)+1.6%+4.1%+19.9%+20.4%+19.4%+12.0%-
EBITDA CAGR (3Y)-2.2%--13.1%+34.6%---
Profitability & leverage
Net income margin+8.3%+12.3%-11.5%+9.8%-32.9%-17.4%+6.9%
Return on capital employed+6.5%+10.7%-3.9%+21.2%-25.8%+4.5%+7.4%
Return on net worth+4.7%+13.2%-69.2%+92.8%-101.5%+17.3%+6.6%
Debt / equity0.020.130.910.570.220.050.06
Long-term debt / equity0.020.040.170.08-30,181.49-17,754.290.00
Interest cover22.0915.47-10.2419.57-0.94-0.3329.58
Efficiency & per share
Fixed asset turnover1.832.022.522.502.421.861.79
Inventory turnover6.257.228.056.848.447.656.43
Debtors turnover6.375.965.904.604.514.304.38
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
Dividend per share (₹)3.000.000.000.000.000.000.00
Book value per share (₹)158.56150.5710.0621.7725.944,358.555,476.91

Investments & Acquisitions by Akums

Akums has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Ankur Drugs and Parabolic Drugs.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Ankur Drugs
CMO specializing in cephalosporins and beta-lactams
ankurdrugs.comMumbai, India1997Apr 2022••••
Parabolic Drugs
APIs, intermediates, and formulations are manufactured and exported.
parabolicdrugs.comChandigarh, India1996Apr 2019••••
Premium access

Complete acquisition details for Akums

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Akums

6 dated milestones of Akums across 20 years, from founding to its latest funding, stage changes and deals.

  1. Founded Akums is founded.
  2. Acquisition Acquires Parabolic Drugs.
  3. Funding First funding round of $70.0M.
  4. Milestone Reaches Minicorn status.
  5. Acquisition Acquires Ankur Drugs.
  6. IPO Lists on the stock exchange (IPO).

Competitors of Akums

Akums has 3 listed competitors in our database, 2 of them funded. They include Jubilant Life Sciences, Nectar Lifesciences and Windlas.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Jubilant Life Sciences
jubl.com1978Noida, India
Company offering a suite of R&D and manufacturing services for small molecules and generics
Nectar Lifesciences
neclife.com1995Chandigarh, India$46.85M175
Cephalosporin APIs and generic formulations are manufactured.
Windlas
windlas.com2001Gurugram, India$12.96M1,264
Biopharma regulatory affairs, quality control, and strategy services are provided.
Premium access

Detailed competitors of Akums

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Akums

The website of Akums (akums.in) receives about 25.5K visits a month and ranks #1,037,095 among all websites worldwide, #1,281 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    25.5K

    ▲ 2.1% vs previous month

  • Unique visitors
    11.8K

    per month

  • Global rank
    #1,037,095

    among all websites

  • Category rank
    #1,281

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Akums. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Alembic Pharmaceuticals
alembicpharmaceuticals.com
100%
23K#2,083,600View details
Ajanta Pharma
ajantapharma.com
95%
20.1K#1,412,069View details
Cadila Pharmaceuticals Limited
cadilapharma.com
93%
18.5K#1,452,788View details
Ciron
cironpharma.com
93%
2.4K#7,858,699View details
ipa-india.org
ipa-india.org
93%
#2,901,611–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Akums

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Akums (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Akums

Akums Launches New Moisturization Formulations for Winter Skincare Season
Media Bulletins • 14 days ago
Akums Drugs And Pharmaceuticals: To Host Analyst And Investor Meeting On September 22 At 10 AM
Exchange Update • 1 month ago
Buy Akums Drugs and Pharmaceuticals; target of Rs 850: ICICI Securities
Moneycontrol • 2 months ago
Akums reports robust Q1 FY27 performance with 13.9% YoY Revenue growth - The Wire
The Wire • 2 months ago
AKUMS: Strong Q1 growth driven by CDMO, margin expansion, and strategic acquisition in cosmetics
Quartr • 2 months ago
Buzzing Stocks: Emcure Pharma gains 3% on USFDA EIR; PFC slips 3% after mixed Q1 earnings
Moneycontrol • 2 months ago
AKUMS: Strong revenue and profit growth, full IPO fund utilisation, and strategic acquisition drive expansion
Quartr • 2 months ago
AKUMS: Q1 FY27 delivered double-digit revenue and profit growth, led by CDMO and API margin gains
Quartr • 2 months ago
Q1 Results 08th Aug Highlights: Delhivery, Anant Raj, Apollo Micro Systems, Akums Drugs Pharma, Aditya Birla Fashion, Ceigall India, PNC Infratech Oswal Pumps to announce Q1 results - The HinduBusinessLine
Thehindubusinessline • 2 months ago
AKUMS: Strong FY 2026 growth driven by CDMO, robust cash flow, and major international contracts
Quartr • 5 months ago
Premium access

Complete news archive for Akums

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akums

Akums was founded in 2004 and raised its 1st funding round 15 years after it was founded.

Akums is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

Akums is a funded company, having raised a total of $70M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $70M, raised on Nov 2019.

Akums has 17,860 employees.

The primary company behind Akums, Akums Drugs And Pharmaceuticals Limited, reported revenue of ₹4,488 Cr for FY 2026, up 6% year on year.

Akums was founded in 2004 and is headquartered in Delhi, India. As a contract development and manufacturing organization in the pharmaceutical sector, formulations are produced and exported across multiple dosage forms, including oral solids, liquids, sterile injectables, hormonals, ointments, cosmetics, Ayurvedics, and nutraceuticals. Therapeutic areas addressed encompass respiratory, neurology, analgesics, cardiovascular, immunomodulators, and supportive care.

Akums's top competitors include Jubilant Life Sciences, Nectar Lifesciences and Windlas.

Yes, Akums is publicly traded on NSE under the ticker symbol AKUMS.

Akums has made 2 acquisitions, including Ankur Drugs, and Parabolic Drugs.

Akums has 1 investor. Key investors include Quadria Capital.

The valuation of Akums is $459.31M as of Nov 2019.

Akums is associated with 6 legal entities: Akums Drugs And Pharmaceuticals Limited, Akums Lifesciences Limited, Akums Healthcare Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available